

HR 4619

Pharmaceutical REPAI Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 8, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 9, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4619>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Higgins, Brian [D-NY-26]	D · NY		Oct 8, 2019
Rep. Wild, Susan [D-PA-7]	D · PA		Oct 8, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 9, 2019
Ways and Means Committee	House	Referred to	Oct 8, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 3	Related bill	Sep 8, 2020: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

Summary (as of Oct 8, 2019)

Pharmaceutical Rebates for Excessive Pricing Above Inflation Act or the Pharmaceutical REPAI Act

This bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under the Medicare prescription drug benefit that cost \$100 or more and for which the average manufacturer price increases faster than inflation.

Actions Timeline

- **Oct 9, 2019:** Referred to the Subcommittee on Health.
- **Oct 8, 2019:** Introduced in House
- **Oct 8, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 8, 2019:** Referred to the Subcommittee on Health.